Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994. (Q53540758)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

Barbara Sperner-Unterweger

31 October 2019

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

R Greil

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

B Holzner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G Kemmler

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Buchowski

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

W Oberaigner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

E Fritsch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S Dirnhofer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

U Rueffer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

V Diehl

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 May 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

698-706

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Alternating drug combinations in the treatment of advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Coronary artery disease mortality in patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (mopp) vs. nitrogen mustard in advanced hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Value of prednisone in combination chemotherapy of stage IV Hodgkin's disease. Report from the British National Lymphoma Investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Leukemia following Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Early menopause in long-term survivors of cancer during adolescence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Semen analysis in Hodgkin's disease before the onset of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Long-term effects of cancer treatment and consequences of cure: cancer survivors enjoy quality of life similar to their neighbours.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Early intensive therapy with autotransplantation for high-risk Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Hodgkin's disease (HD): a historical perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

The quality of life of long-term survivors of Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Quality of life in long-term survivors of adult-onset cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Hodgkin disease in the elderly. A registry-based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Survival of the older patient compared with the younger patient with Hodgkin's disease. Influence of histologic type, staging, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

The prognosis of Hodgkin's disease in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Second cancer risk following Hodgkin's disease: a 20-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Hodgkin's disease in patients over sixty years old

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Influence of clinical trials on current treatment strategy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

What value is given to quality of life assessment by health professionals considering response to palliative chemotherapy for advanced cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

National Cancer Institute sponsored cooperative clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900025-8

7 January 2021

10.1016/S0959-8049(99)00025-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10505027%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference